Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition).
10.3760/cma.j.cn112152-20220713-00489
- Collective Name:Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association;;Expert Committee for Monitoring the Clinical Application of Antitumor Drugs;;Breast Cancer Expert Committee of National Cancer Quality Control Center;;Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center
- Publication Type:Journal Article
- Keywords:
Antibody-drug conjugate;
Cytotoxic drug;
Malignant tumors;
Monoclonal antibody;
Safety management
- MeSH:
Humans;
Immunoconjugates/therapeutic use*;
Consensus;
Neoplasms/drug therapy*;
Antineoplastic Agents/adverse effects*;
Antibodies, Monoclonal/therapeutic use*
- From:
Chinese Journal of Oncology
2023;45(9):741-762
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugates (ADCs) are a class of targeted biological agents that link cytotoxic drugs to monoclonal antibodies through linkers. The monoclonal antibody targets tumor cells and transports small-molecule cytotoxic drugs for specific delivery and minimal off-target side effects. September 30, 2022, 14 anti-tumor ADC drugs have been approved for marketing in the world, and four ADCs have been approved in China. With the improvement of the clinical accessibility of ADC drugs, clinicians urgently need to understand the molecular characteristics and mechanisms of ADCs, and clarify the indications for rational use of drugs. Patients' survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions. In view of this, on the basis of the "Expert Consensus on the Clinical Application of Antibody-drug Conjugates for the Treatment of Malignant Tumors (2020 edition)" , Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association fully combines the existing clinical research evidence and the feasibility of current ADC drugs in China to update the consensus content. This consensus aims to provide a systematic overview of ADC drugs, so as to provide practical and effective suggestions and references for clinicians to apply and manage ADC drugs more accurately.
